ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report - Takeaways - MDSpire

ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report

  • By

  • Danyang Zhou

  • Ying Wu

  • Siyu Guo

  • Ping Li

  • Guangxin Li

  • Mengqi Yang

  • Shubin Wang

  • Fang Yang

  • June 2, 2026

  • 0 min

Share

  • 1

    Brain metastases occur in 30-55% of patients with HER2-positive metastatic breast cancer, complicating treatment options.

  • 2

    Circulating tumor DNA (ctDNA) monitoring can detect disease activity earlier than traditional imaging methods.

  • 3

    A 35-year-old woman with HER2-positive breast cancer achieved a pathological complete response after standard therapy.

  • 4

    Treatment with trastuzumab deruxtecan and pyrotinib led to intracranial disease control for 17 months in the reported case.

  • 5

    The findings suggest the need for prospective evaluation of ctDNA-guided treatment strategies in HER2-positive brain metastases.

Original Source(s)

ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report

  • by Danyang Zhou, Ying Wu, Siyu Guo, Ping Li, Guangxin Li, Mengqi Yang, Shubin Wang, Fang Yang

  • June 2, 2026

Related Content

Automated bone marrow cell classification using ensemble learning: performance, generalization, and clinical interpretability

Case Report: Response to ivosidenib in patients with cholangiocarcinoma: a clinical perspective with illustrative cases

Predicting survival in oral squamous cell carcinoma via integrated analysis of tumor budding and tertiary lymphoid structures